Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Receivables (2020 - 2025)

Treace Medical Concepts' Receivables history spans 6 years, with the latest figure at $42.2 million for Q4 2025.

  • For Q4 2025, Receivables rose 3.42% year-over-year to $42.2 million; the TTM value through Dec 2025 reached $42.2 million, up 3.42%, while the annual FY2025 figure was $42.2 million, 3.42% up from the prior year.
  • Receivables reached $42.2 million in Q4 2025 per TMCI's latest filing, up from $33.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $42.2 million in Q4 2025 to a low of $10.0 million in Q2 2021.
  • Average Receivables over 5 years is $25.2 million, with a median of $25.5 million recorded in 2023.
  • Peak YoY movement for Receivables: soared 65.03% in 2023, then dropped 6.14% in 2024.
  • A 5-year view of Receivables shows it stood at $18.6 million in 2021, then soared by 57.24% to $29.2 million in 2022, then skyrocketed by 30.5% to $38.1 million in 2023, then increased by 7.09% to $40.8 million in 2024, then rose by 3.42% to $42.2 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Receivables are $42.2 million (Q4 2025), $33.0 million (Q3 2025), and $30.3 million (Q2 2025).